<DOC>
	<DOCNO>NCT02382380</DOCNO>
	<brief_summary>This study individual decrease kidney function whose doctor order Magnetic Resonance Imaging ( MRI ) . Because kidney function decrease , patient usually receive intravenous contrast material improve accuracy MRI finding . The purpose study evaluate safety benefit use contrast material call Gadoterate patient decrease kidney function .</brief_summary>
	<brief_title>Evaluation Gadoterate Patients With Decreased Kidney Function</brief_title>
	<detailed_description>Gadolinium-based intravenous contrast agent widely use enhancement MRI finding . However , agent implicate vary degree nephrotoxicity therefore usually used patient renal dysfunction . Gadoterate Gadolinium agent previous study indicate safe patient decrease kidney function . The purpose study evaluate safety efficacy use Gadoterate patient population . Participants schedule MRI choose either receive Gadoterate contrast part MRI receive Gadoterate part MRI .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N , N ' , N '' , N '' '-tetraacetate</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Glomerular filtration rate ( GFR ) less 30 ml/min dialysis Being send MRI examination course routine clinical evaluation one follow indication : suspect known head/neck/brain mass , hepatic mass , renal mass , pancreatic mass , prostate mass , well evaluation carotid abdominopelvic vasculature . Pregnant lactating female Planned initiation chemotherapy surgery within 72 hour MRI exam Hemodynamic instability acute coronary syndrome History nephrotoxic medication within 2 week exam Less 18 year old Known decrease GFR ( within past 3 month ) 20 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Contrast Agent</keyword>
	<keyword>Gadoterate</keyword>
</DOC>